PAPAIJV
LUMO

Paragon Associates & Paragon Associates II Joint Venture’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,000
Closed -$500K – 20
2021
Q2 		$500K Buy
+50,000
New +$557K 0.67% 15

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's LUMO Position: Q3 2021 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2021, closing a stake of 50,000 shares — an estimated $500K sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in LUMO in Q2 2021 and held it in 1 quarter. The position peaked at $500K in Q2 2021. 37 funds tracked by Wall St. Rank hold LUMO as of Q3 2021.

  • Paragon Associates & Paragon Associates II Joint Venture reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Paragon Associates & Paragon Associates II Joint Venture sold 50,000 Lumos Pharma, Inc. Common Stock shares in Q3 2021, an estimated $500K.
  • Paragon Associates & Paragon Associates II Joint Venture first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Paragon Associates & Paragon Associates II Joint Venture's Lumos Pharma, Inc. Common Stock position peaked at $500K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2021.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q3 2021, filed 15 Nov 2021.